科伦博泰生物-B（06990）：公司信息更新报告：sac-TMT商业化进展顺利，2026年销售放量可期

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company achieved a revenue of 2.058 billion yuan in 2025, representing a year-on-year growth of 6.5%. The revenue from drug sales significantly increased by 949.8% to 543 million yuan, while income from licensing and cooperation agreements decreased by 19.6% to 1.498 billion yuan. The net profit attributable to shareholders was -382 million yuan, a decline of 43.2% year-on-year, primarily due to increased sales expenses related to the expansion of the commercialization team and marketing activities [5][6] - The company has adjusted its revenue forecasts for 2026 to 2028 to 2.230 billion yuan, 4.179 billion yuan, and 6.647 billion yuan respectively, down from previous estimates. The current stock price corresponds to a price-to-earnings ratio of -175.5 for 2026, 234.8 for 2027, and 52.8 for 2028. The long-term development of the company is viewed positively due to the clear trend of commercialization and multiple products being included in the national medical insurance catalog [5][6] Financial Summary - In 2025, the company reported a revenue of 2.058 billion yuan, with a year-on-year growth of 6.5%. The projected revenues for 2026, 2027, and 2028 are 2.230 billion yuan, 4.179 billion yuan, and 6.647 billion yuan respectively, indicating a growth trajectory [8] - The net profit is expected to be -639 million yuan in 2026, with a significant recovery projected in 2027 to 478 million yuan and further growth to 2.124 billion yuan in 2028. The gross margin is expected to be 66.2% in 2026, improving to 82.7% by 2028 [8][10] - The company has a total market capitalization of 99.291 billion HKD and a circulating market capitalization of 69.307 billion HKD, with a current stock price of 425.80 HKD [1][8] Product and Market Development - The core product, sac-TMT, has received approval for multiple indications and is expected to see significant sales growth in 2026. The company has successfully included sac-TMT, Tagolizumab, and Westimab N01 in the new national medical insurance catalog, which is anticipated to drive rapid sales growth [6] - The company has established a commercialization team of over 600 people, covering more than 1,200 hospitals, which lays a solid foundation for product sales. Additionally, sac-TMT has received approvals for new indications, enhancing its market potential [6][7]